Publications by authors named "Daniel Waterkamp"

Claim this Profile
C
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.
Neil H Segal, Ignacio Melero, Victor Moreno, Neeltje Steeghs, Aurelien Marabelle, Daniel Waterkamp

Nat Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Stephen V Liu, D Ross Camidge, Scott N Gettinger, Giuseppe Giaccone, Rebecca S Heist, Daniel Waterkamp

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies.
Jessica Davies, Manali Patel, Cesare Gridelli, Filippo de Marinis, Daniel Waterkamp

PLoS One· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello

Lancet· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Daniel Waterkamp

Nat Commun· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Daniel Waterkamp

Lancet· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
Herbert I Hurwitz, Niall C Tebbutt, Fairooz Kabbinavar, Bruce J Giantonio, Zhong-Zhen Guan, Daniel Waterkamp

Oncologist· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
David Cunningham, Istvan Lang, Eugenio Marcuello, Vito Lorusso, Janja Ocvirk, Daniel Waterkamp

Lancet Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolation of targeted AAV2 vectors from novel virus display libraries.
Daniel A Waterkamp, Oliver J Müller, Ying Ying, Martin Trepel, Jürgen A Kleinschmidt

J Gene Med· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis